Skip to content
Calculator
Evidence: MediumPeptideNot FDA ApprovedEndothelin-B agonist peptideApproved in India (2023) · not in the USIschaemic stroke

Sovateltide

An endothelin-B agonist approved in India for stroke

Sovateltide is a synthetic peptide modelled on endothelin-1 that selectively switches on the endothelin-B receptor. In rat stroke models it raised blood flow and encouraged neural repair, and in May 2023 India approved it, as Tycamzzi, for ischaemic stroke treated within 24 hours. The two trials behind that approval were small and run by its developer; it is not approved in the US.

Used in human trials: 0.3 µg/kg per dose, Three doses 3 hours apart on days 1, 3 and 6, Intravenous (Trial: acute ischaemic stroke within 24 hours (phase 3, India)) Details ↓

Overview

What is it?

Endothelin-1 is best known as a powerful vessel constrictor acting through the endothelin-A receptor. Its other receptor, endothelin-B, does different things in the brain, and sovateltide was designed to hit only that one. In rats with middle cerebral artery occlusion, a 2024 meta-analysis of six studies found it lowered neurological deficits and improved motor performance at day 7, with smaller infarcts and more neural progenitor differentiation. Individual studies showed restored blood flow in the injured hemisphere in young rats and recovery of neuronal differentiation markers. All of that evidence is in rats.

The clinical programme ran in India. A 40-patient randomised, double-blind phase 2 trial added sovateltide to standard care within 24 hours of stroke; it was well tolerated, and more patients improved by two or more points on the modified Rankin Scale (60% against 40%, p = 0.05). The phase 3 trial randomised 158 patients and gave 0.3 µg/kg intravenously three times, 3 hours apart, on days 1, 3 and 6, starting about 18 hours after onset. At 90 days, the odds of independent function (mRS 0 to 2) were 2.75 times higher and 72.5% against 51.3% improved by at least two mRS points. Brain bleeding occurred in about 9% of both groups.

Both trials were funded by the developer, Pharmazz, and the phase 3 data were analysed by an author who is a company employee holding its patents and stock. The phase 3 trial excluded patients given thrombectomy and used imputation for missing 90-day data. Its authors say a multinational trial is needed for US approval, and ClinicalTrials.gov lists a 514-patient phase 3 that is recruiting. A later observational study from routine Indian care reported better outcomes, but cannot separate the drug from who received it.

Before stroke, the same molecule was tested in cancer as SPI-1620, meant to open tumour blood vessels and help chemotherapy reach the tumour. With docetaxel in 30 patients with advanced biliary cancer, it missed its target of five months' progression-free survival. Animal work extends to spinal cord injury and newborn brain injury, and trials are listed in spinal cord injury, neonatal hypoxic-ischaemic encephalopathy and Alzheimer's disease.

OR 2.75
Odds of independence at 90 days
Phase 3, 158 patients · PMID 39542995
0.3 µg/kg
Three IV doses on days 1, 3 and 6
3 hours apart · PMID 39542995
India 2023
Approved for ischaemic stroke
Not in the US · PMID 37486545
Science

Mechanism of Action

Sovateltide is a selective agonist of the endothelin-B receptor, the brain-protective arm of the endothelin system.

🎯

Endothelin-B only

Activates ETB receptors without the vessel-constricting ETA action of endothelin-1.

🌱

Repair after stroke

In rats it increased neuronal differentiation markers, VEGF and NGF, and reduced infarct size and cell death.

🩸

Blood flow

Raised cerebral blood flow in rats; a transient fall in blood pressure weakened with repeat doses.

Evidence

Published Research

Studies of sovateltide, from their PubMed abstracts.

Human2024

Phase 3 in ischaemic stroke

In 158 randomised patients, mRS 0-2 at day 90 was more frequent with sovateltide (OR 2.75, 95% CI 1.37-5.57), as was NIHSS 0-5 (OR 2.67); 72.50% vs 51.28% improved by 2 or more mRS points; intracranial haemorrhage 8.75% vs 8.97%.

PMID: 39542995
Human2021

Phase 2 in ischaemic stroke

In 40 patients, sovateltide was well tolerated with no drug-related adverse events; mRS improvement of 2 or more points occurred in 60% vs 40% (p = 0.0519) and Barthel Index gains of 40 or more in 64% vs 36% (p = 0.0112).

PMID: 33428177
Human2026

Routine care in India

In a prospective observational study at one Indian hospital, stroke patients given sovateltide as part of routine care had better functional score distributions at 30, 60 and 90 days than those on standard therapy alone; the authors stress the findings are associations, not causation.

PMID: 41731809
Review2023

First approval

Sovateltide was approved in India in May 2023 for cerebral ischaemic stroke within 24 hours of onset, and is in development for hypoxic-ischaemic encephalopathy, spinal cord injury and Alzheimer's disease.

PMID: 37486545
Animal2024

Meta-analysis of rat stroke studies

Across six rat MCAO studies, IRL-1620 significantly lowered neurological deficit and improved motor performance at day 7; infarct volume and progenitor differentiation also improved; all included studies were in rats.

PMID: 38724864
Human2017

SPI-1620 with docetaxel in biliary cancer

In 30 patients with advanced biliary tract cancer, SPI-1620 plus docetaxel did not reach the target PFS of 5 months: median PFS 2.6 months, response rate 10.3%, overall survival 4.87 months.

PMID: 28632730
Animal2018

Young rats after stroke

In young rats with middle cerebral artery occlusion, IRL-1620 improved neurological and motor scores, restored blood flow in the injured hemisphere by day 7 and reduced infarct volume.

PMID: 30406063
Animal2020

Neuronal differentiation

In rats after permanent stroke, sovateltide restored markers of neuronal differentiation (HuC/HuD, NeuroD1) to sham levels, reduced infarct volume and DNA damage, and improved function at day 7.

PMID: 32574518
Animal2022

Neonatal hypoxic-ischaemic injury

In neonatal rats, sovateltide alone or with therapeutic hypothermia reduced oxidative stress and cell death and raised ETB receptor, VEGF and NGF in the brain.

PMID: 34826534
Animal2024

Spinal cord injury in rats

After spinal cord injury, sovateltide improved motor recovery from day 7, reaching pre-injury levels, and raised the pain threshold, while vehicle-treated rats plateaued.

PMID: 38443708
Animal2009

Blood pressure tolerance

In rats, repeated mid-to-high doses caused falling blood pressure that weakened with each injection (40% to 22%), mediated by ETA receptors, while lower renal and higher cerebral blood flow persisted.

PMID: 19666119
Dosing

Dosing Data

The phase 3 trial gave 0.3 µg/kg intravenously three times, about 3 hours apart, on days 1, 3 and 6 after stroke, alongside standard care.

Approved only in India; investigational elsewhere. Doses below come from the trial.
ProtocolDoseFrequencyDurationRoute
Trial: acute ischaemic stroke within 24 hours (phase 3, India) Human studyPMID 395429950.3 µg/kg per doseThree doses 3 hours apart on days 1, 3 and 6One weekIntravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Hospital dosing
Sovateltide is given in micrograms per kilogram by intravenous injection in hospital; there is no self-administered dose.
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no regulator's label that says in what form Sovateltide is supplied. It is prepared and given by clinical staff, not bought and mixed at home: the next part says where.

Mixing a vial: a worked example

Nothing to mix at home, and no syringe units to work out: Sovateltide is prepared and given by clinical staff, in hospital, for acute stroke.

In the carded trial it was given into a vein to patients within 24 hours of an ischaemic stroke.

Source: PMID 39542995 (a study carded under Research below).

Storage before and after mixing

Unknown: no label on file says how Sovateltide is stored. It is kept and prepared by the hospital or clinic that gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.

How it is taken

As it was given in human studies: Intravenous (Three doses 3 hours apart on days 1, 3 and 6; Trial: acute ischaemic stroke within 24 hours (phase 3, India)).

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Trial: acute ischaemic stroke within 24 hours (phase 3, India): One week.

When effects appear: unknown; no source on this page gives a time to effect for Sovateltide. Results reported in the studies are under Published Research.

Source: Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: No drug-related adverse events in the 40-patient phase 2 stroke trial; Intracranial haemorrhage at a similar rate to placebo in phase 3 (8.75% vs 8.97%); Febrile neutropenia and neutropenia when combined with docetaxel in cancer. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Sovateltide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the trials above”).

Interactions

Unknown: a PubMed search for human interaction studies of Sovateltide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Sovateltide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Sovateltide's expected mass, 1,820.9 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: Not FDA Approved (Approved in India in May 2023 for cerebral ischaemic stroke within 24 hours of onset (PubMed 37486545)). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the trials above.

● No drug-related adverse events in the 40-patient phase 2 stroke trial
● Intracranial haemorrhage at a similar rate to placebo in phase 3 (8.75% vs 8.97%)
● Febrile neutropenia and neutropenia when combined with docetaxel in cancer

Contraindications & Cautions

No US label exists; the phase 3 trial excluded these patients.

● Intracranial haemorrhage
● Recurrent stroke
● Patients receiving endovascular therapy
Questions

Frequently Asked Questions

?What is sovateltide?

A synthetic peptide analogue of endothelin-1 that selectively activates the endothelin-B receptor, approved in India in 2023 as Tycamzzi for ischaemic stroke treated within 24 hours.

?How strong is the evidence that sovateltide helps stroke patients?

Moderate at best: a 40-patient phase 2 and a 158-patient phase 3, both funded by the developer, with the phase 3 data analysed by a company employee. A larger multinational trial is recruiting.

?Is sovateltide available in the US?

No. It has no FDA approval, and its developers say a multinational trial will be needed for US approval.

?How does it differ from nerinetide?

Both are peptides tested in acute stroke. Nerinetide interferes with the neuronal protein PSD-95, while sovateltide activates endothelin-B receptors to raise blood flow and support repair.

?How is it given?

In the phase 3 trial, as three intravenous injections of 0.3 µg/kg about 3 hours apart on days 1, 3 and 6 after the stroke, on top of standard care. Patients treated with thrombectomy were excluded.

?Does it raise the risk of brain bleeding?

Not in the phase 3 trial: brain bleeding occurred in about 9% of patients in both the sovateltide and placebo groups. In rats, repeated doses briefly lowered blood pressure, an effect that weakened with each dose.

Bibliography

References

  1. [other] PubChem CID 16130933, Sovateltide: formula C86H117N17O27, molecular weight 1820.9. Read October 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/16130933
  2. [fda] FDA. Drugs@FDA (openFDA): no application on record for sovateltide. Read October 3, 2026.
  3. [registry] ClinicalTrials.gov API v2, read October 3, 2026: NCT04047563 (phase 3, 158, completed), NCT04046484 (phase 2, 40, completed), NCT05691244 (phase 3, 514, recruiting), NCT05955326 (phase 4, 160, active), NCT04054414 (spinal cord injury, phase 2, recruiting), NCT05514340 (hypoxic-ischaemic encephalopathy, phase 2, recruiting), NCT04052737 (Alzheimer's, phase 2, 80, completed).
  4. [clinical-trial] Gulati A, et al. "Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial." Drugs, 2024;84(12):1637-1650. PMID: 39542995.
  5. [clinical-trial] Gulati A, et al. "Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke." CNS Drugs, 2021;35(1):85-104. PMID: 33428177.
  6. [pubmed] Keam SJ. "Sovateltide: First Approval." Drugs, 2023;83(13):1239-1244. PMID: 37486545.
  7. [pubmed] Moustakas D, et al. "The Effects of IRL-1620 in Post-ischemic Brain Injury: A Systematic Review and Meta-analysis of Experimental Studies." Neurocrit Care, 2024;41(2):665-680. PMID: 38724864.
  8. [clinical-trial] Kim R, et al. "Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment." Br J Cancer, 2017;117(2):189-194. PMID: 28632730.
  9. [pubmed] Kandasamy G, et al. "Real-world functional outcomes of sovateltide as an adjunct to standard therapy in acute ischemic stroke: A prospective observational study." Medicine (Baltimore), 2026;105(8):e47760. PMID: 41731809.
  10. [pubmed] Cifuentes EG, et al. "Neuroprotective Effect of IRL-1620, an Endothelin B Receptor Agonist, on a Pediatric Rat Model of Middle Cerebral Artery Occlusion." Front Pediatr, 2018;6:310. PMID: 30406063.
  11. [pubmed] Ranjan AK, et al. "Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke." Can J Physiol Pharmacol, 2020;98(9):659-666. PMID: 32574518.
  12. [pubmed] Ramos MD, et al. "Neuroprotective Effect of Sovateltide (IRL 1620, PMZ 1620) in a Neonatal Rat Model of Hypoxic-Ischemic Encephalopathy." Neuroscience, 2022;480:194-202. PMID: 34826534.
  13. [pubmed] Mavridis T, et al. "Sovateltide (ILR-1620) Improves Motor Function and Reduces Hyperalgesia in a Rat Model of Spinal Cord Injury." Neurocrit Care, 2024;41(2):455-468. PMID: 38443708.
  14. [pubmed] Leonard MG, et al. "Repeated administration of ET(B) receptor agonist, IRL-1620, produces tachyphylaxis only to its hypotensive effect." Pharmacol Res, 2009;60(5):402-10. PMID: 19666119.

Sources & Citations

Studies were read from their PubMed abstracts; the Indian approval comes from a 2023 drug review. Read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03